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Abstract
Multiple cell cycle regulatory proteins play an important role in oncogenesis. Cancer
cells may arise from dysregulation of various genes involved in the regulation of the
cell cycle. In addition, cyclin-dependent kinase inhibitors are regarded as key
regulators for cancer cell proliferation. Accordingly, permission of impaired cells by
cell cycle checkpoints suppresses carcinogenesis. P53, a multifunctional protein,
controls G1-S transition, which is the strongest tumor suppressor involved in the
regulation of cell cycle. The p53 is stimulated by cellular stress like oxidative stress.
Upon activation, p53 leads to cell cycle arrest and promotes DNA repair; otherwise,
it induces apoptosis. One of the target effectors of p53 is the phosphatase and tensin
homolog deleted on chromosome 10 (PTEN). The tumor suppressor PTEN is a dual-
specificity phosphatase which has protein phosphatase activity and lipid phosphatase
activity that antagonizes PI3K/AKT activity. The PI3K/AKT cell survival pathway is
shown as regulator of cell proliferation. The p53 cooperates with PTEN and might be
an essential barrier in development of cancers. BRCA1 plays an important role in DNA
repair processes related to maintenance of genomic integrity and control of cell
growth. The inactivation of these tumor suppressor proteins confers a growth
advantage of cancer. This chapter summarizes the function of several tumor suppres‐
sors in the cell cycle regulation.
Keywords: p53, PTEN, BRCA1, AKT, MDM2, p21WAF1, protein interaction, pro‐
tein expression, cell signaling, DNA repair, cell cycle regulation
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1. Introduction
Mechanisms of cell cycle are predominantly controlled by p53 tumor suppressor [1, 2]. The
p53 transcription factor can bring G1 arrest of the cell cycle by transactivating several down‐
stream molecules [3, 4], which regulates various signaling pathways involved in the cellular
response to genome stress and DNA damage. Through the stress-induced activation, p53
triggers the expression of target genes that protect the genetic reliability of cells [5]. Germinal
mutations of the p53 gene constitute an etiological base of Li-Fraumeni syndrome, which is a
sporadic heterogeneous autosomal dominant inherited oncogenic disorder [6]. BRCA1, a
famous breast cancer tumor suppressor, is associated with breast and ovarian cancer risk and
genetic susceptibility [7]. Studies have shown that p53 as well as BRCA1 plays a key role in
DNA damage responses [8]. In addition, BRCA1 could work together with phosphatase and
tensin homolog deleted in chromosome 10 (PTEN), which is also a tumor suppressor gene that
is deleted or mutated in a range of human cancers [7, 9], and may be a critical protection in
development of several tumors [7, 9]. Actually, PI3K/AKT pathway is constitutively active in
BRCA1 defective human cancer cells [10]. Both PTEN and BRCA1 genes are documented as
one of the most frequently deleted and/or mutated in various human cancers. Loss or decrease
of these PTEN or BRCA1 activities, by either mutation or reduced expression, seems to have
a critical role in various cancer developments. PTEN prevents the activation of PI3K/AKT
pathway by dephosphorylating the membrane phospholipid PIP3 [11]. Loss of PTEN results
in increased AKT recruitment to the plasma membrane and stimulates the signaling pathway.
Mutations in PTEN genome are the cause of distinctive hamartoma syndromes (PTEN-related
Proteus syndrome, Cowden syndrome, Proteus-like syndrome, Bannayan-Riley-Ruvalcaba
syndrome) with higher risk for a development of several tumors [12]. Furthermore, BRCA1
and PTEN have been shown to be involved in a complex linkage on the interaction with the
p53 as presented in Figure 1. Although they are functionally distinct, mutual cooperation has
been proposed. These tumor suppressors regulate diverse cellular activities including DNA
damage repair, cell cycle arrest, cell differentiation, cell proliferation, cell migration, and cell
apoptosis [13]. Importantly, mutations in all of these genes have been associated with increased
risk of developing cancers. This review summarizes the function of the tumor suppressors in
DNA repair and cell cycle regulation. We will also discuss the role of cellular signaling through
protein interaction pathways for the potential implications in the fundamental DNA repair
and cell cycle regulation.
2. Characteristics of p53, PTEN, and BRCA1
The p53 gene encodes a nuclear 393-amino-acid protein which is a transcription factor (Figure
2). The p53 tumor suppressor plays an essential role in regulating cellular processes including
cell cycle arrest, apoptosis, cell metabolism, and cell senescence. Inactivation of p53 gene is
related to the development of most types of cancers [14], suggesting that p53 also plays a critical
role in preventing normal cells to becoming cancer cells. In addition, importance of p53 as an
inherited cancer susceptibility gene has been revealed in the Li-Fraumeni syndrome [15].
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Multiple mechanisms have been shown to accomplish the regulation of p53 activity, which
controls the selectivity of p53 for specific transcriptional targets [16]. Discharge of p53 from
normal repression by binding with molecules such as MdmX or Mdm2 may be a crucial step
in the activation of p53 [17, 18]. Functional activation of p53 links with its higher DNA-binding
ability, transcriptional activation, then increased expression of the target genes of p53, which
are all related to cell cycle regulation and/or cellular apoptosis.
PTEN tumor suppressor gene is also frequently deleted and mutated in several human cancers
[19]. The gene product is a 53-kDa protein with homology to tensin and protein tyrosine
phosphatases. Human genomic locus of the PTEN consists of 9 exons on chromosome 10q23.3
encoding a 5.5-kb mRNA that postulates a 403-amino-acid open reading frame [20]. Schematic
construction of the predicted PTEN protein is presented in Figure 2. The PTEN protein consists
of amino-terminal phosphatase, carboxyl-terminal C2, and PDZ (PSD-95, DLG1, and ZO-1)
binding domains [21]. The structure offers PTEN with its preference for acidic phospholipid
substrates including phosphatidylinositol 3,4,5-triphosphate (PIP3), as the PTEN CX5R(S/T)
motif resides within an active site that surrounds the catalytic core with three basic residues,
which are critical for PTEN lipid phosphatase activity [22]. PTEN negatively regulates the
activity of PI3K/AKT signaling through converting PIP3 into phosphatidylinositol 4,5-
bisphosphate (PIP2) [23]. PIP3 is the principal second messenger of the PI3K pathway that
Figure 1. Schematic illustration of the integrative signaling model of tumor suppressors including p53, PTEN, and
BRCA1 is shown. Typical examples of molecules known to act on the cell proliferation, DNA damage response, and
cell cycle regulation via the regulatory pathway are shown. Note that some critical pathways have been omitted for
clarity.
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mediates receptor tyrosine kinase (RTK) signaling to the cell survival kinase AKT. In general,
growth factors stimulate RTKs, then activate PI3K and AKT. Upon activation, the inositol ring
phosphorylated by PI3K serves to fix AKT to the plasma membrane, where it is sequentially
phosphorylated and completely activated by 3-phosphoinositide-dependent kinases PDK1
and PDK2 [24]. Subsequently, activated AKT phosphorylates target proteins involved in cell
survival, cell cycling, proliferation, and cell migration [25]. PTEN may act as a regulator of
keeping basal levels of PIP3 under a threshold for those signaling activation. Overexpression
of PTEN inhibits cell growth by supporting cell cycle arrest, which requires the lipid phos‐
phatase activity of PTEN [26], which correlates with reduced levels and nuclear localization
of cyclin-D1 [27], an important molecule of cell cycle regulated by PTEN and AKT. In addition,
PTEN induces the cell cycle arrest by upregulating the cell cycle inhibitor p27KIP1 [28].
However, studies have shown many tumor suppressive activities for PTEN that are working
within the nucleus, where catalysis of PIP3 does not appear to characterize a main function of
the enzyme. The nuclear PTEN activities may include the regulation of genomic stability and
several gene expression, indeed despite that the central role of PTEN is as a negative regulator
of the PI3K pathway. PTEN activity can be regulated by posttranslational regulation including
phosphorylation, oxidation, and acetylation [29, 30].
BRCA1 cDNA encodes for 1863-amino-acid protein with two nuclear localization signals (NLS)
and an amino terminal conserved RING finger motif which is the shared motif present in E3
ubiquitin ligases [31] (Figure 2). The RING finger domain interacts with E2 ubiquitin ligases
and applies E3 ligase activity [32]. Knock-in mice with deficient BRCA1 activity exhibit diverse
genomic instability and tumor-forming phenotypes [33]. Exon 11 encodes an unstructured
region of the BRCA1 protein that is phosphorylated by the ATM and Chk2 kinases in a DNA-
damage-dependent manner [34, 35], and the specific function of BRCA1 may be regulated by
Figure 2. Schematic structures of p53, PTEN, and BRCA1 proteins are shown. The predicted consensual domain struc‐
tures for each protein are depicted. The functionally key sites including the sites of protein phosphorylation are shown.
Note that the sizes of protein are modified for clarity. Activation = transactivation domain; PxxP = proline-rich region;
RING = (Really Interesting New Gene) finger domain, NLS = Nuclear Localization Signal, BRCT = BRCA1 C Terminus;
C2 domain = a protein structural domain involved in targeting proteins to cell membranes; PDZ = a common structural
domain in signaling proteins (PSD95, Dlg, ZO-1, etc.)
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phosphorylation. BRCA1 becomes more phosphorylated after exposure to the DNA-damaging
agents [36]. The carboxyl-terminal domain of BRCA1 is involved in association with specific
phosphorylated proteins [37]. Because BRCA1 plays a crucial role in maintaining genome
stability, the mutation of BRCA1 is associated with increased genomic instability in cells, which
consequently accelerates the mutation rate of the other critical genes. Inherited BRCA1
germline mutation is revealed as a genetic susceptibility leading to high risk of breast and
ovarian cancers [38]. Although BRCA1 gene mutations are rare in breast and/or ovarian
cancers, BRCA1 protein expression is often decreased in sporadic cancer specimens. Princi‐
pally, the role of BRCA1 in cell cycle control has been understood by its ability to interact with
various cyclin proteins and various cyclin-dependent kinases [39, 40].
3. Relationship among PTEN, p53, BRCA1, and MDM2
The PTEN and p53 complex augments the p53-DNA binding and the transcriptional action
[41], which may upregulate the expression of PTEN itself and p21WAF1, which is a key
molecule involved in cell cycle arrest [42]. Indeed, a superior function of p53 is to work as a
transcription factor by attaching to the definite DNA consensus sequence on the p53 responsive
genes. Consequently, p53 indirectly inhibits production of PIP3 by inducing the expression of
this PTEN. In addition, PTEN associates with p53 and regulates the transcriptional activity of
p53 by modulating its DNA binding. PTEN is also required for the maintenance of p53
acetylation [43], which is essential for target gene transcription. An adjacent function of PTEN
as a tumor suppressor is accomplished through the stabilization of the p53 protein. PTEN and
p53 form a complex in the nucleus under hypoxic conditions [44]. Nuclear PTEN is sufficient
to reduce cancer progression in a p53-dependent manner [45]. In addition, the nuclear PTEN
seems to mediate DNA damage repair through modulating the activity of DNA repair
molecules. The PI3K-dependent activation of AKT indirectly leads to the inhibition of p53
functions by activating another tumor suppressor MDM2 [46]. Activation of AKT has the
potential of reducing the p53-mediated cell cycle checkpoints through phosphorylation and
appropriation of p21WAF1 [47]. By the way, several PI3K inhibitors favorably reduce prolif‐
eration of BRCA1-defective breast cancer cells. For example, BEZ235 inhibits not only PI3K/
mTOR but also ATM/ATR [48, 49]. It is possible that ATM pathways are involved in upregu‐
lation of the PI3K/AKT pathway in BRCA1-defective cancer cells. In contrast, BRCA1 may
regulate the PI3K/AKT pathway by acting on upstream kinases of AKT. Overexpression of
wild-type BRCA1 could further reduce basal phosphorylation of AKT levels in MCF7 cells [10,
50]. In addition, reduced levels of PTEN are associated with radio-resistance which can be
suppressed by the ectopic PTEN expression [51, 52].
MDM2 controls carcinogenesis, whose mRNA level is also transcriptionally regulated by p53
in response to DNA damage [53]. MDM2 protein and subcellular localization are post-
translationally modulated by AKT [53]. Besides inhibiting the PI3K/AKT signaling, PTEN also
promotes translocation of the MDM2 into the nucleus. Furthermore, PTEN modulates MDM2
transcription by negatively regulating its promoter [41]. PTEN controls MDM2 promoter
activity through its lipid phosphatase activity, independent of the p53 activity [53]. In PTEN-
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null cells, MDM2 promoter activity is upregulated, resulting in increased MDM2 expression
[53]. MDM2 also regulates the activity of p53 protein by transferring the nuclear p53 protein
into the cytoplasm and by promoting the degradation of the p53 protein [54]. PTEN upregu‐
lates the p53 level as well as its activity by downregulating MDM2 transcription [55]. However,
in the absence of p53, PTEN may have a role in inhibiting MDM2-mediated carcinogenesis
through regulation of MDM2 transcription. The p53 and MDM2 complex transports from the
nucleus into the cytoplasm, where MDM2 serves as an E3 ubiquitin ligase [56]. Therefore, p53
and MDM2 form a regulatory feedback loop in which p53 positively regulates MDM2 activity.
Inactivation of either gene should result in lower protein levels of the other gene. The ability
of PTEN to inhibit the nuclear entry of MDM2 increases the cellular content. The BRCA1
carboxyl-terminal region can also stimulate transcription of the p53-responsive promoter of
MDM2 [57]. BRCA1 has been shown to affect the gene transcription, but how it does so remains
elusive. Essentially, the most important molecule for the DNA damage recognition may be
ATM, which is a key checkpoint kinase that phosphorylates various proteins including BRCA1
and/or p53 in response to the DNA damage [58]. BRCA1 activates the CDK inhibitor p21WAF1
and the p53 tumor suppressor protein, which regulates several genes that control the cell cycle
checkpoints [59, 60]. Inhibition of this important DNA repair pathway seems to block the
mechanisms that are required for normal cell survival in the presence of oncogenic mutations
due to DNA damage.
4. Involvement of the p53-PTEN-MDM2-BRCA1 loop in cell cycle
regulation
The levels of p53 could vary and is positively related to the amount of DNA damage [61]. Low
levels of p53 may induce cell cycle arrest, whereas high levels of p53 may induce apoptosis.
On the other hand, growth factor-activated AKT signaling supports progression of cell cycle
by acting on several factors involved in the G1/S or G2/M cell cycle transitions. Because the
ability of p53 to induce cell cycle arrest and/or cell apoptosis can be provoked by cell survival
signals including the AKT pathway, the cell growth signal circuitously leads to the inhibition
of p53 by triggering its negative regulators [62]. The p53 protein also regulates BRCA1
transcription both in vitro and in vivo, and BRCA1 participates in p53 accumulation after
irradiation through regulation of its phosphorylation and MDM2 expression [63]. MDM2 can
act as a modifier of BRCA1 mutant and may accelerate breast and ovarian carcinogenesis [64].
In addition, p53 and PTEN are known to interact and to regulate each other at the transcription
as well as protein level, which could be at the important control machinery for switching
between survival and death. Given the ability of PTEN to stabilize p53 protein through
provoking the AKT-MDM2 complex or by increasing p53 acetylation, the decreased p53
activity in PTEN-lacking tumor cells could be plausible. PTEN and BRCA1 may be regulated
and interact with each other at multiple levels including transcription, protein modulation,
and protein stability. Therefore, the p53-PTEN-MDM2-BRCA1 loop in cell cycle regulation
now becomes dominant (Figure 3). These cross talks are frequently a combination of recipro‐
cally antagonistic pathways, which may often serve as an additional regulatory effect on the
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expression of key genes involved in cell cycle and carcinogenesis. Interestingly, genistein,
which is a soy isoflavone, brings regulation between PTEN and p53 to support cell cycle arrest
[65]. Genistein induces PTEN expression and nuclear accumulation, which elicits a sequence
of PTEN-dependent nuclear p53 accumulation and recruitment of the PTEN/p53 complex to
the p53 binding sites [65], then attenuates expression of cell proliferative genes [65]. In addition,
genistein inhibits cell proliferation and induces cell apoptosis more proficiently in BRCA1-
mutant cells than in cells expressing wild-type BRCA1 protein [66]. BRCA1-mutant breast
cancer cells are highly sensitive to genistein treatment, and AKT could be genistein targets in
these cells [66]. Accordingly, genetic variants in the molecules of p53, PTEN, BRCA1, and
MDM2 may play roles in tumor suppressor network mediating a susceptibility to cancer.
Remarkably, it has also been presented that zinc deficiency modulates the p53-PTEN-BRCA1-
MDM2 signaling network in normal cells [67].
Figure 3. Suggestion of various regulatory loops involving the p53-PTEN-MDM2-BRCA1 network on cell cycle regula‐
tion. Interactions are shown as arrows to mean activation, while hammerheads, to mean inhibition. Expression of these
tumor suppressor genes is regulated by genetic, epigenetic, and transcriptional changes, which may result in the DNA
repair and cell cycle regulation in a cell. Downregulation of the function can contribute to genomic instability, which
promotes malignant transformation of cells. Note that some critical pathways have been omitted for clarity.
5. Perspective
In unstressed cells, p53 may be regularly kept at low levels by its negative regulator MDM2.
This feedback loop among the p53-PTEN-MDM2-BRCA1 may function for the accurate
regulation of the DNA repair and cell cycle (Figure 3). When stressed, the tumor suppressor
p53 predominantly induces cell cycle arrest or apoptosis in the response to DNA damage.
Indeed, the regulation is crucial for the effective design of novel cancer therapeutics. Further
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mechanistic studies are needed in order to understand the exact molecular mechanisms for
the effective treatment of cancers with the functional alterations in the cellular signaling loop.
Targets within this pathway could provide strategies therapeutically valuable for several
cancer treatments. It is important to investigate the linkage among the molecules, and
elucidation of interaction-specific functions may provide insight into regulatory aspects of
these tumor suppressors as well as opportunities for therapeutic intervention. Such molecular
interactions may sustain the biological plausibility that the combination of variants of the p53-
PTEN-MDM2-BRCA1 network could result in more comprehensive. Genetic analysis for
germline mutations in these key genes allows for the identification of characters at increased
risk of cancers. However, they may be regulated and interact with each other at multiple levels
including transcription, protein modulation, and protein stability. Obviously, understanding
the regulation is crucial for the effective design of novel cancer prevention and therapeutics.
Further studies are needed to understand molecular mechanisms in more detail.
6. Abbreviations
ATM: ataxia telangiectasia-mutated
BRCA1: breast cancer susceptibility gene 1
HDM2: human homolog of MDM2
LOH: Loss of heterozygosity
MDM2: murine double minute 2
NEDL1: NEDD4-like ubiquitin protein ligase-1
NF-κB: nuclear factor kappaB
NLS: Nuclear Localization Signal
mTOR: mammalian target of rapamycin
PDZ: PSD-95, DLG1, and ZO-1
PEST: proline, glutamic acid, serine and threonine
PTEN: phosphatase and tensin homolog deleted on chromosome 10
PIP2: phosphatidylinositol 4,5- bisphosphate
PIP3: phosphatidylinositol 3,4,5-triphosphate
PI3K: phosphoinositide-3 kinase
RING: really interesting new gene finger domain
RTK: receptor tyrosine kinase
ROS: reactive oxidative species
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